Remogliflozin | B2082

Remogliflozin is a potent sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Potential drug for treatment of type 2 diabetes.

Remogliflozin is a potent sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Potential drug for treatment of type 2 diabetes.

B2082 | Remogliflozin DataSheet

Alternate Name/Synonyms: (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1Hpyrazol-3-yloxy)tetrahydro-2H-pyran-3,4,5-triol

Appearance: White solid

Formulation: N/A

CAS Number: 329045-45-6

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₃H₃₄N₂O₇

Molecular Weight: 450.53

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (>40 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor

MDL Number: N/A

PubChem CID: 9846588

SMILES: CC1=C(C(=NN1C(C)C)OC2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(C=C3)OC(C)C

InChi: InChI=1S/C23H34N2O7/c1-12(2)25-14(5)17(10-15-6-8-16(9-7-15)30-13(3)4)22(24-25)32-23-21(29)20(28)19(27)18(11-26)31-23/h6-9,12-13,18-21,23,26-29H,10-11H2,1-5H3/t18-,19-,20+,21-,23+/m1/s1

InChi Key: GSINGUMRKGRYJP-VZWAGXQNSA-N